WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002028395) PHOSPHORIC ACID SALT OF AN INTEGRIN RECEPTOR ANTAGONIST
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/028395    International Application No.:    PCT/US2001/030647
Publication Date: 11.04.2002 International Filing Date: 01.10.2001
Chapter 2 Demand Filed:    22.04.2002    
IPC:
A61K 31/55 (2006.01), C07D 471/04 (2006.01)
Applicants: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US) (For All Designated States Except US).
MEISSNER, Robert, S. [US/US]; (US) (For US Only).
XU, Wei [US/US]; (US) (For US Only)
Inventors: MEISSNER, Robert, S.; (US).
XU, Wei; (US)
Common
Representative:
MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US)
Priority Data:
60/237,534 04.10.2000 US
Title (EN) PHOSPHORIC ACID SALT OF AN INTEGRIN RECEPTOR ANTAGONIST
(FR) SEL D'ACIDE PHOSPHORIQUE TIRE D'UN ANTAGONISTE D'UN RECEPTEUR DE L'INTEGRINE
Abstract: front page image
(EN)The phosphoric acid salt of 3-(2-methoxy-pyrimidin-5-yl)-5-oxo-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid is a potent antagonist of the integrin $g(a)$g(n)$g(b)3 receptor and is useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salt as well as pharmaceutical compositions and methods of use.
(FR)le sel d'acide phosphorique d'acide 3-(2-méthoxy-pyrimidin-5-yl)-5-oxo-9-(6,7,8,9-tétrahydro-5H-pyrido[2,3-b]azépin-2-yl) nonanoïque, qui est un antagoniste puissant du récepteur $g(a)$g(n)$g(b)3 de l'intégrine, convient bien pour la prévention et/ou le traitement de l'ostéoporose et des la resténose vasculaire ainsi que d'états liés à une angiogenèse excessive tels que la dégénérescence maculaire, la rétinopathie diabétique, l'athérosclérose, l'arthrite inflammatoire, le cancer, et la métastatisation de tumeurs. L'invention concerne également une technique de préparation de ce nouveau sel ainsi que des compositions pharmaceutiques et des méthodes d'utilisation.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)